-
1
-
-
84904035686
-
Adjuvant radiotherapy versus wait-and-see ffter radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial
-
T. Wiegel, D. Bartkowiak, and D. Bottke et al. Adjuvant radiotherapy versus wait-and-see ffter radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial Eur Urol 66 2014 243 250
-
(2014)
Eur Urol
, vol.66
, pp. 243-250
-
-
Wiegel, T.1
Bartkowiak, D.2
Bottke, D.3
-
2
-
-
84870485783
-
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomized controlled trial (EORTC trial 22911)
-
M. Bolla, H. van Poppel, and B. Tombal et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomized controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
-
(2012)
Lancet
, vol.380
, pp. 2018-2027
-
-
Bolla, M.1
Van Poppel, H.2
Tombal, B.3
-
3
-
-
59549095954
-
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial
-
I.M. Thompson, C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial J Urol 181 2009 956 962
-
(2009)
J Urol
, vol.181
, pp. 956-962
-
-
Thompson, I.M.1
Tangen, C.M.2
Paradelo, J.3
-
4
-
-
84856365558
-
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy
-
A.J. Stephenson, M. Bolla, and A. Briganti et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy Eur Urol 61 2012 443 451
-
(2012)
Eur Urol
, vol.61
, pp. 443-451
-
-
Stephenson, A.J.1
Bolla, M.2
Briganti, A.3
-
5
-
-
33751018522
-
Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial
-
I.M. Thompson, C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial JAMA 296 2006 2329 2335
-
(2006)
JAMA
, vol.296
, pp. 2329-2335
-
-
Thompson, I.M.1
Tangen, C.M.2
Paradelo, J.3
-
6
-
-
1542532754
-
A proportional hazards model for the subdistribution of a competing risk
-
J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Amer Stat Assoc 94 1999 496 509
-
(1999)
J Amer Stat Assoc
, vol.94
, pp. 496-509
-
-
Fine, J.P.1
Gray, R.J.2
-
7
-
-
0033526309
-
Natural history of progression after PSA elevation following radical prostatectomy
-
C.R. Pound, A.W. Partin, and M.A. Eisenberg et al. Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
-
(1999)
JAMA
, vol.281
, pp. 1591-1597
-
-
Pound, C.R.1
Partin, A.W.2
Eisenberg, M.A.3
-
8
-
-
34447332283
-
Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy
-
C. Parker, M.R. Sydes, and C. Catton et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy BJU Int 99 2007 1376 1379
-
(2007)
BJU Int
, vol.99
, pp. 1376-1379
-
-
Parker, C.1
Sydes, M.R.2
Catton, C.3
-
9
-
-
84904041507
-
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: Background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial
-
M. Pearse, C. Fraser-Browne, and I.D. David et al. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial BJU Int 113 Suppl S2 2014 7 12
-
(2014)
BJU Int
, vol.113
, Issue.SUPPL. S2
, pp. 7-12
-
-
Pearse, M.1
Fraser-Browne, C.2
David, I.D.3
|